What is fractional heparin?

fractional heparin, also known as low molecular weight heparin (LMWH), is a synthetic anticoagulant drug used to treat thrombosis. Fraged heparin, derived from naturally occurring nephractional heparin, is more predictable in use as a medicine and has fewer short -term and long -term side effects. There are a number of methods for the production of LMWH, each process creates a medicine with different biological properties. Since 2011, research has been in the best use of LMWH. In health conditions, such as thrombosis of deep era, the only LMWH injection may stop the growth of clots, reducing the risk of lung embolism patient. In addition, LMWH can prevent the formation of clots in high -risk individuals such as obese, older and patients undergoing surgery. In all cases, however, fractional heparin cannot break down the clots already formed. The doctor may have the use of a combination of blood directors, anticoagulant drugs and surgery to destroy the clot. NephractionalHeparin, collected from natural sources such as cows and pigs, has a different range of efficacy due to a change in the molecular weight of the compound. For example, the use of nephraphioned heparin can excessively inhibit the ability of the body to clot blood. In a weakened patient, this side effect may be deadly. Although there are many forms of LMWH, the use of one will lead to predictable and consistent patient results.

pharmaceutical companies produce fractionated heparin through various processes. There are six main production methods, each creating a type of LMWH that has slightly different anticoagulant effects. This series of efficacy is adaptable to patients because it allows a physician to choose an anticoagulant that will have the desired effect but not to be in unnecessary risk to the patient. Another advantage of all forms of LMWH is that the medicine has a lower risk of side effects than nephraccionovaHeparin. For example, a LMWH patient has a lower risk of osteoporosis for a long time.

Research continues to improve the best use of fractional heparin. Research published in 2003 showed that a certain form of LMWH was more effective than another form in preventing thrombosis in cancer patients. This research in expansion proves that the medical community still has to learn a lot about LMWH. It is very likely that over time LMWH will be able to save even more lives.